On Wednesday, in a statement, CStone Pharmaceuticals stated, a unit of Pfizer Inc has agreed to acquire a 9.9% stake in it for $200 million (HK$1.55 billion). With the news reaching the market the shares of the Hong Kong-listed biopharmaceutical firm surged by 39.6% to HK$12.98 – its highest since October 2, 2019.

Cstone’s stock is on track for a fourth straight session of gains, marking its best gains since it got listed in February 2019.

In a statement Shanghai-based CStone said, the deal will allow it to focus on product development and strengthen its ability to commercialize CS1001 – an anti-PD-L1 monoclonal antibody.

Pfizer Corporation has agreed to purchase 115.93 million new shares of China-based CStone at HK$13.37 apiece, representing 43.8% premium over the closing price of HK$9.30 on Tuesday.

CStone, which focuses on immuno-oncology medicines, said it had granted a Pfizer unit an exclusive license to commercialize CS1001 in mainland China.

Categories: Creativity, Economy & Finance, Entrepreneurship, HR & Organization, Strategy

Tags: acquire, anti PD L1, bio pharmaceutical, China based, commercialise, CS1001, Cstone, CStone Pharmaceuticals, exclusive licence, Hong Kong, immuno oncology, mainland China, medicines, monoclonal antibody, Pfizer Inc, pharmaceutical, premium, product development, Shanghai based, shares, stake